Aduro BioTech Inc (ADRO) - Financial and Strategic SWOT Analysis Review

January 2018 | 44 pages | ID: A8BB3E0BBCAEN
GlobalData

Abstracts

Aduro BioTech Inc (ADRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products under development are intended for the treatment of multiple indications, including pancreatic, lung, ovarian, prostate cancers, mesothelioma and glioblastoma. The company collaborates with various pharmaceutical companies to expand its products and technology platforms. Aduro BioTech is headquartered in Berkeley, California, the US.

Aduro BioTech Inc Key Recent Developments

Oct 31,2017: Aduro Biotech Reports Third Quarter 2017 Financial Results
Oct 09,2017: Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
Aug 02,2017: Aduro Biotech Reports Second Quarter 2017 Financial Results
Jul 27,2017: Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017
May 02,2017: Aduro Biotech Reports First Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Aduro BioTech Inc - Key Facts
Aduro BioTech Inc - Key Employees
Aduro BioTech Inc - Major Products and Services
Aduro BioTech Inc - History
Aduro BioTech Inc - Company Statement
Aduro BioTech Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Aduro BioTech Inc - Business Description
R&D Overview
Aduro BioTech Inc - Corporate Strategy
Aduro BioTech Inc - SWOT Analysis
SWOT Analysis - Overview
Aduro BioTech Inc - Strengths
Aduro BioTech Inc - Weaknesses
Aduro BioTech Inc - Opportunities
Aduro BioTech Inc - Threats
Aduro BioTech Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Aduro BioTech Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Oct 31, 2017: Aduro Biotech Reports Third Quarter 2017 Financial Results
Oct 09, 2017: Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
Aug 02, 2017: Aduro Biotech Reports Second Quarter 2017 Financial Results
Jul 27, 2017: Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017
May 02, 2017: Aduro Biotech Reports First Quarter 2017 Financial Results
Apr 20, 2017: Aduro Biotech Announces Management Promotions
Mar 02, 2017: Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference
Mar 01, 2017: Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results
Jan 26, 2017: Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Aduro BioTech Inc, Key Facts
Aduro BioTech Inc, Key Employees
Aduro BioTech Inc, Major Products and Services
Aduro BioTech Inc, History
Aduro BioTech Inc, Other Locations
Aduro BioTech Inc, Subsidiaries
Aduro BioTech Inc, Key Competitors
Aduro BioTech Inc, Ratios based on current share price
Aduro BioTech Inc, Annual Ratios
Aduro BioTech Inc, Annual Ratios (Cont.1)
Aduro BioTech Inc, Interim Ratios
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Aduro BioTech Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Aduro BioTech Inc, Performance Chart (2012 - 2016)
Aduro BioTech Inc, Ratio Charts
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

NewLink Genetics Corp
Idera Pharmaceuticals Inc
Akebia Therapeutics Inc
Advaxis Inc